Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn's Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Gastroenterology and Hepatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn's Disease
Clin. Gastroenterol. Hepatol. 2021 Dec 20;[EPub Ahead of Print], N Van den Berghe, B Verstockt, S Vermeire, D Thomas, P DeclerckFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.